Halozyme Therapeutics (HALO) Earnings Date & Reports

Key Takeaways

• Halozyme Therapeutics is expected to report its third-quarter 2026 results in early November, following back-to-back earnings beats.
• Second-quarter 2026 total revenue climbed 48% year over year to $481.0 million, with non-GAAP diluted EPS of $2.28 beating consensus by roughly 26%.
• Management raised full-year 2026 guidance to $1.835–$1.910 billion in revenue and $8.65–$9.00 in non-GAAP diluted EPS.
• Investors will focus on ENHANZE royalty growth, which is diversifying beyond blockbuster products like DARZALEX SC.
• Analyst estimates heading into the print point to revenue near $482 million, with EPS projections ranging from about $2.06 to $2.25.

Earnings Context and Why It Matters

Halozyme Therapeutics is a biopharmaceutical company best known for its ENHANZE drug-delivery technology, which enables certain medicines to be administered as quick subcutaneous (under-the-skin) injections rather than lengthy intravenous infusions. The upcoming third-quarter report matters because it will test whether the company's royalty engine can sustain its exceptional momentum. Halozyme has now beaten Wall Street expectations in consecutive quarters and raised its 2026 outlook in August. For investors, this print offers a fresh read on partner product uptake, the durability of high-margin royalty revenue, and whether management's ambitious growth targets remain on track.

Earnings Expectations

Analyst estimates for the third quarter of 2026 vary, but consensus figures generally point to total revenue near $482 million and earnings per share (EPS) projections ranging from approximately $2.06 to $2.25. That compares with second-quarter revenue of $481.0 million and non-GAAP diluted EPS of $2.28, when results handily exceeded expectations.

The most closely watched metric will again be royalty revenue, which surged 50% year over year to $307.7 million in the second quarter, driven by continued uptake of ENHANZE-enabled products including VYVGART Hytrulo and DARZALEX SC. Investors will also monitor adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), which reached $328.8 million last quarter, as well as any updates to full-year 2026 guidance.

Historically, Halozyme shares have reacted positively to strong prints: the stock gained roughly 3.6% in after-hours trading following first-quarter results and jumped about 20% the day after its second-quarter report, which included an upward guidance revision.

AI Screener

For traders looking to identify opportunities ahead of earnings season and beyond, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool that filters the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for both retail and professional investors monitoring events like the Halozyme quarterly earnings report.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report remains constructive after Halozyme's August beat and guidance raise pushed the stock to record territory. By mid-October 2026, shares were trading around $122, reflecting continued investor confidence in the royalty-driven business model. That said, expectations are elevated, which raises the bar for a positive surprise. Key risk factors include ongoing patent litigation with Merck, the company's dependence on partner product performance, and rising research and development plus selling, general, and administrative expenses tied to the recent Hypercon and Surf Bio acquisitions. A guidance confirmation or further increase could reinforce the rally, while any royalty slowdown or legal setback could weigh on the stock.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, investors should watch several catalysts tied to Halozyme's long-term growth roadmap. The first is ENHANZE royalty diversification. Management has emphasized that revenue is expanding beyond DARZALEX SC to include products such as VYVGART Hytrulo, OCREVUS SC, and other recently launched subcutaneous therapies. Sustained uptake across this broader portfolio will be central to meeting the company's raised 2026 targets.

A second factor is the development pipeline. Halozyme projects up to 13 additional ENHANZE partner products could reach approval in the 2029-plus timeframe, and the company has guided for the first Hypercon phase I clinical trial starts in the first half of 2027. Progress on these timelines, along with any new collaboration and licensing agreements, will shape the market's view of growth durability beyond 2028.

Investors should also monitor capital allocation. Halozyme announced a new $1 billion share repurchase authorization in 2026 and expects to buy back at least $400 million of shares this year. Finally, the status of the Merck patent litigation and any commentary on operating expenses from the Hypercon and Surf Bio integrations will be important swing factors. Together, these signals will help determine whether Halozyme's high-margin, royalty-focused model can continue delivering the growth the market has come to expect.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations